In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Zynerba Pharmaceuticals, Inc.. Trade Record

NASDAQ:ZYNE Zynerba Pharmaceuticals, Inc. stock gains 19.66% Exit Apr 18, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ZYNE Apr 2, 2019, priceSeries
About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.

Trade Information
Trade Type
Entry Date
Apr 2, 2019
Entry Price
Sell Date
Apr 18, 2019
Sell Price
Net Gain
Hold Time
12 Trading Days